Key questions regarding safety of pharmacological management of rheumatoid arthritis (RA) with traditional and biologic disease-modifying antirheumatic drugs (DMARD).
| Perioperative Care |
| 1. Should treatment with methotrexate be suspended prior to surgery? |
| 2. Should treatment with biologic DMARD be suspended prior to surgery? |
| Latent Tuberculosis Infection (LTBI) |
| 3. For which biologic DMARD therapies is screening for LTBI recommended? |
| 4. What is the role of interferon-gamma release assays (IGRA) in the diagnosis of LTBI in patients with RA? |
| 5. Which patients with RA should be considered for treatment with tuberculosis prophylaxis? |
| 6. When can treatment with biologic DMARD be started in RA patients receiving tuberculosis prophylaxis? |
| Vaccination |
| 7. Which vaccines are indicated in patients with RA? |
| 8. If indicated, when should inactive vaccines be administered in patients with RA treated with traditional and/or biologic DMARD? |
| 9. If indicated, when should live vaccines be administered in patients with RA treated with traditional and/or biologic DMARD? |
| Malignancy |
| 10. Should treatment with traditional and/or biologic DMARD be modified in patients with active malignancy? |
| 11. Should treatment with traditional and/or biologic DMARD be modified in patients with a history of lymphoma? |
| 12. Should treatment with traditional and/or biologic DMARD be modified in patients with a history of nonmelanoma skin cancer? |
| 13. Should treatment with traditional and/or biologic DMARD be modified in patients with a history of solid tumor? |